de Goldman Sachs Vertex Pharmaceuticals VRTX Historial de posiciones en acciones
Compró
Mantenido
Vendió
| Trimestre | Valor de mercado | Estado | Núm. de acciones |
Cambio en la participación | Valor operado | Peso en el portafolio | Posición de la cartera | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | USD 1233 M | Comprar |
2,481,761
+63,886
| +3% | +USD 28.3 M | 0.11% | 150 |
|
|
2026
Q1 | USD 1080 M | Comprar |
2,417,875
+663,757
| +38% | +USD 310 M | 0.12% | 152 |
|
|
2025
Q4 | USD 795 M | Comprar |
1,754,118
+269,460
| +18% | +USD 116 M | 0.1% | 182 |
|
|
2025
Q3 | USD 581 M | Vender |
1,484,658
-447,102
| -23% | -USD 187 M | 0.07% | 253 |
|
|
2025
Q2 | USD 860 M | Comprar |
1,931,760
+197,166
| +11% | +USD 90.9 M | 0.12% | 153 |
|
|
2025
Q1 | USD 841 M | Comprar |
1,734,594
+332,860
| +24% | +USD 155 M | 0.14% | 130 |
|
|
2024
Q4 | USD 564 M | Comprar |
1,401,734
+43,200
| +3% | +USD 20 M | 0.09% | 201 |
|
|
2024
Q3 | USD 632 M | Vender |
1,358,534
-703,965
| -34% | -USD 338 M | 0.1% | 187 |
|
|
2024
Q2 | USD 967 M | Comprar |
2,062,499
+661,539
| +47% | +USD 287 M | 0.16% | 110 |
|
|
2024
Q1 | USD 586 M | Vender |
1,400,960
-83,974
| -6% | -USD 35.5 M | 0.1% | 194 |
|
|
2023
Q4 | USD 604 M | Vender |
1,484,934
-210,391
| -12% | -USD 77.7 M | 0.11% | 179 |
|
|
2023
Q3 | USD 590 M | Vender |
1,695,325
-120,547
| -7% | -USD 42.2 M | 0.13% | 152 |
|
|
2023
Q2 | USD 639 M | Comprar |
1,815,872
+104,141
| +6% | +USD 35.1 M | 0.14% | 135 |
|
|
2023
Q1 | USD 539 M | Comprar |
1,711,731
+39,358
| +2% | +USD 11.8 M | 0.12% | 151 |
|
|
2022
Q4 | USD 483 M | Vender |
1,672,373
-48,374
| -3% | -USD 14.7 M | 0.12% | 166 |
|
|
2022
Q3 | USD 498 M | Comprar |
1,720,747
+673,107
| +64% | +USD 194 M | 0.13% | 131 |
|
|
2022
Q2 | USD 295 M | Vender |
1,047,640
-196,067
| -16% | -USD 52.5 M | 0.07% | 253 |
|
|
2022
Q1 | USD 325 M | Comprar |
1,243,707
+56,330
| +5% | +USD 13.4 M | 0.07% | 275 |
|
|
2021
Q4 | USD 261 M | Vender |
1,187,377
-206,385
| -15% | -USD 40.1 M | 0.05% | 368 |
|
|
2021
Q3 | USD 253 M | Comprar |
1,393,762
+15,745
| +1% | +USD 3.07 M | 0.05% | 344 |
|
|
2021
Q2 | USD 278 M | Vender |
1,378,017
-284,549
| -17% | -USD 59.5 M | 0.06% | 300 |
|
|
2021
Q1 | USD 357 M | Comprar |
1,662,566
+101,920
| +7% | +USD 22.4 M | 0.09% | 204 |
|
|
2020
Q4 | USD 369 M | Vender |
1,560,646
-483,081
| -24% | -USD 111 M | 0.09% | 192 |
|
|
2020
Q3 | USD 556 M | Comprar |
2,043,727
+543,029
| +36% | +USD 150 M | 0.16% | 109 |
|
|
2020
Q2 | USD 436 M | Vender |
1,500,698
-252,282
| -14% | -USD 68.4 M | 0.13% | 137 |
|
|
2020
Q1 | USD 417 M | Vender |
1,752,980
-115,419
| -6% | -USD 26.5 M | 0.15% | 127 |
|
|
2019
Q4 | USD 409 M | Comprar |
1,868,399
+259,060
| +16% | +USD 52.4 M | 0.1% | 192 |
|
|
2019
Q3 | USD 273 M | Vender |
1,609,339
-350,181
| -18% | -USD 61.9 M | 0.08% | 269 |
|
|
2019
Q2 | USD 359 M | Vender |
1,959,520
-342,113
| -15% | -USD 59.8 M | 0.1% | 187 |
|
|
2019
Q1 | USD 423 M | Vender |
2,301,633
-244,307
| -10% | -USD 45.1 M | 0.13% | 138 |
|
|
2018
Q4 | USD 422 M | Vender |
2,545,940
-59,559
| -2% | -USD 10.3 M | 0.13% | 123 |
|
|
2018
Q3 | USD 502 M | Vender |
2,605,499
-746,306
| -22% | -USD 133 M | 0.13% | 139 |
|
|
2018
Q2 | USD 570 M | Vender |
3,351,805
-89,262
| -3% | -USD 13.8 M | 0.15% | 112 |
|
|
2018
Q1 | USD 561 M | Comprar |
3,441,067
+210,866
| +7% | +USD 34.4 M | 0.14% | 133 |
|
|
2017
Q4 | USD 484 M | Comprar |
3,230,201
+533,497
| +20% | +USD 79 M | 0.12% | 169 |
|
|
2017
Q3 | USD 410 M | Vender |
2,696,704
-82,840
| -3% | -USD 12.5 M | 0.1% | 184 |
|
|
2017
Q2 | USD 358 M | Vender |
2,779,544
-876,362
| -24% | -USD 105 M | 0.09% | 201 |
|
|
2017
Q1 | USD 400 M | Vender |
3,655,906
-226,338
| -6% | -USD 19.9 M | 0.11% | 159 |
|
|
2016
Q4 | USD 286 M | Comprar |
3,882,244
+287,541
| +8% | +USD 23.4 M | 0.08% | 238 |
|
|
2016
Q3 | USD 313 M | Vender |
3,594,703
-42,704
| -1% | -USD 4.04 M | 0.09% | 192 |
|
|
2016
Q2 | USD 313 M | Vender |
3,637,407
-772,565
| -18% | -USD 66.8 M | 0.1% | 180 |
|
|
2016
Q1 | USD 351 M | Comprar |
4,409,972
+1,540,048
| +54% | +USD 139 M | 0.12% | 162 |
|
|
2015
Q4 | USD 361 M | Comprar |
2,869,924
+530,388
| +23% | +USD 64 M | 0.11% | 171 |
|
|
2015
Q3 | USD 244 M | Comprar |
2,339,536
+717,467
| +44% | +USD 92.2 M | 0.08% | 247 |
|
|
2015
Q2 | USD 200 M | Vender |
1,622,069
-149,768
| -8% | -USD 18.9 M | 0.06% | 344 |
|
|
2015
Q1 | USD 209 M | Vender |
1,771,837
-98,221
| -5% | -USD 11.8 M | 0.07% | 342 |
|
|
2014
Q4 | USD 222 M | Vender |
1,870,058
-164,325
| -8% | -USD 18.5 M | 0.07% | 323 |
|
|
2014
Q3 | USD 228 M | Vender |
2,034,383
-785,372
| -28% | -USD 74.8 M | 0.07% | 283 |
|
|
2014
Q2 | USD 267 M | Vender |
2,819,755
-869,911
| -24% | -USD 61 M | 0.08% | 259 |
|
|
2014
Q1 | USD 261 M | Vender |
3,689,666
-762,239
| -17% | -USD 60.4 M | 0.09% | 247 |
|
|
2013
Q4 | USD 331 M | Vender |
4,451,905
-1,905,026
| -30% | -USD 133 M | 0.11% | 187 |
|
|
2013
Q3 | USD 482 M | Vender |
6,356,931
-388,244
| -6% | -USD 30.9 M | 0.18% | 100 |
|
|
2013
Q2 | USD 540 M | Comprar |
+6,745,175
| Nuevas | +USD 497 M | 0.21% | 77 |
|
Otros fondos que tienen VRTX en su cartera
Posición de Goldman Sachs en VRTX: resumen de T2 2026
Goldman Sachs aumentó su participación en Vertex Pharmaceuticals (VRTX) en 2.6% durante T2 2026, al comprar aproximadamente USD 28.3 M y elevar la posición a 2,481,761 acciones con un valor de USD 1233 M. La posición representa 0.11% de la cartera y ocupa el puesto #150.
Goldman Sachs reportó por primera vez una posición en VRTX en T2 2013 y la ha mantenido durante 53 trimestres desde entonces. Al cierre de T2 2026, 1,770 fondos que sigue Wall St. Rank mantienen una posición en VRTX.
- Al cierre de T2 2026, Goldman Sachs tenía 2,481,761 acciones de Vertex Pharmaceuticals con un valor de USD 1233 M.
- Goldman Sachs compró 63,886 acciones de Vertex Pharmaceuticals en T2 2026, por un monto estimado de USD 28.3 M.
- Vertex Pharmaceuticals representó 0.11% de la cartera de Goldman Sachs en T2 2026 y fue su posición número 150.
- Goldman Sachs reportó por primera vez una posición en Vertex Pharmaceuticals en T2 2013 y la ha mantenido durante 53 trimestres desde entonces.
- Al cierre de T2 2026, 1,770 fondos que sigue Wall St. Rank tenían Vertex Pharmaceuticals en cartera.
Según el Informe 13F de Goldman Sachs correspondiente a T2 2026, presentado el 14 ago 2026.